Intellia Therapeutics, Inc.
NTLA
In Vitro & In Vivo Diagnostic Substances
Mkt Cap
$2.179BPE
-4.49Debt
-Cash
$172MEV
-FCF
-$418.1MP/E Ratio
-4.49Debt
-Cash
$172MEV
-FCF
-$418.1MCharts data: {"Earnings":[{"time":"2015-12-30","value":-12397000},{"time":"2016-12-30","value":-31634000},{"time":"2017-12-30","value":-67543000},{"time":"2018-12-30","value":-85343000},{"time":"2019-12-30","value":-99533000},{"time":"2020-12-30","value":-134231000},{"time":"2021-12-30","value":-267892000},{"time":"2022-12-30","value":-474186000},{"time":"2023-12-30","value":-481192000}],"Sales":[{"time":"2015-12-30","value":6044000},{"time":"2016-12-30","value":16479000},{"time":"2017-12-30","value":26117000},{"time":"2018-12-30","value":30434000},{"time":"2019-12-30","value":43103000},{"time":"2020-12-30","value":57994000},{"time":"2021-12-30","value":33053000},{"time":"2022-12-30","value":52121000},{"time":"2023-12-30","value":36275000}],"Net Margins":[{"time":"2015-12-30","value":-2.051125082726671},{"time":"2016-12-30","value":-1.9196553188907093},{"time":"2017-12-30","value":-2.586169927633342},{"time":"2018-12-30","value":-2.8041992508378786},{"time":"2019-12-30","value":-2.3091896155720018},{"time":"2020-12-30","value":-2.3145670241749148},{"time":"2021-12-30","value":-8.104922397361813},{"time":"2022-12-30","value":-9.097791677059151},{"time":"2023-12-30","value":-13.265113714679531}],"Assets":[{"time":"2015-12-30","value":82139000},{"time":"2016-12-30","value":298969000},{"time":"2017-12-30","value":376235000},{"time":"2018-12-30","value":347315000},{"time":"2019-12-30","value":334280000},{"time":"2020-12-30","value":676322000},{"time":"2021-12-30","value":1294464000},{"time":"2022-12-30","value":1520114000},{"time":"2023-12-30","value":1300977000}],"Stockholders Equity":[{"time":"2015-12-30","value":-21201000},{"time":"2016-12-30","value":209837000},{"time":"2017-12-30","value":300597000},{"time":"2018-12-30","value":277920000},{"time":"2019-12-30","value":269881000},{"time":"2020-12-30","value":527072000},{"time":"2021-12-30","value":1040244000},{"time":"2022-12-30","value":1235584000},{"time":"2023-12-30","value":1050169000}],"ROE":[{"time":"2015-12-30","value":0.5847365690297628},{"time":"2016-12-30","value":-0.15075510991865115},{"time":"2017-12-30","value":-0.2246961879193738},{"time":"2018-12-30","value":-0.3070775762809442},{"time":"2019-12-30","value":-0.36880328737480594},{"time":"2020-12-30","value":-0.25467298585392506},{"time":"2021-12-30","value":-0.2575280414979563},{"time":"2022-12-30","value":-0.3837747979902621},{"time":"2023-12-30","value":-0.45820434615761846}],"ROA":[{"time":"2015-12-30","value":-0.1632476655425559},{"time":"2016-12-30","value":-0.10581030140248654},{"time":"2017-12-30","value":-0.1795234361502784},{"time":"2018-12-30","value":-0.2616356909433799},{"time":"2019-12-30","value":-0.3182003111164293},{"time":"2020-12-30","value":-0.2019496630303317},{"time":"2021-12-30","value":-0.20691962078512804},{"time":"2022-12-30","value":-0.3014010791295916},{"time":"2023-12-30","value":-0.39608002293660843}]}
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
![QDEL Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>QDEL</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth -
Earnings Stability -
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -210% | -190% | -260% | -280% | -230% | -230% | -810% | -910% | -1.3K% | -920% |
| ROA | -16% | -11% | -18% | -26% | -32% | -20% | -21% | -30% | -40% | -41% |
| ROE | 58% | -15% | -22% | -31% | -37% | -25% | -26% | -38% | -46% | -47% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -631.6%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -224.17%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -28.1%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -1.79%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -33.83%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -2.3%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | - | - | - | - | - | - |
| Debt Equity | - | - | - | - | - | - | - | - | - | - |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | - | - |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 12% | 3.6% | -14% | -30% | -19% |
| Net Income | - | - | - | - | - |
| Stockholders Equity | 26% | 30% | 26% | -15% | -0.78% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +3.57%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -19.18%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +41.33%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +30.46%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -0.78%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +43.26%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.